Table 2.
Results of the meta-analysis for pCR, pPR, and Grade≥ 3 irAEs rate.
| Outcomes | No. of studies |
Heterogeneity | Overall effect size |
95% CI of overall effect |
Weight(%) |
|---|---|---|---|---|---|
| I2(%) p-value | |||||
| PCR | |||||
| PD-(L)1 inhibitors alone | 8 | 41.71 0.10 | 0.27 | 0.19–0.35 | 33.83 |
| PD-(L)1 inhibitors plus other ICI | 5 | 72.73 0.01 | 0.41 | 0.21–0.62 | 17.34 |
| PD-(L)1 inhibitors plus chemotherapy | 11 | 42.80 0.06 | 0.43 | 0.35–0.50 | 48.83 |
| Overall pooled PCR | 24 | 57.40 0.00 | 0.36 | 0.30–0.42 | 100 |
| PPR | |||||
| PD-(L)1 inhibitors alone | 6 | 65.79 0.01 | 0.36 | 0.22–0.51 | 26.26 |
| PD-(L)1 inhibitors plus other ICI | 4 | 0.00 0.43 | 0.51 | 0.39–0.62 | 17.56 |
| PD-(L)1 inhibitors plus chemotherapy | 11 | 55.15 0.01 | 0.61 | 0.53–0.69 | 56.19 |
| Overall pooled PPR | 21 | 60.94 0.00 | 0.53 | 0.46–0.60 | 100 |
| Grade≥ 3 irAEs rate | |||||
| PD-(L)1 inhibitors alone | 7 | 0.00 0.84 | 0.07 | 0.04–0.11 | 44.05 |
| PD-(L)1 inhibitors plus other ICI | 4 | 59.17 0.06 | 0.31 | 0.16–0.47 | 24.36 |
| PD-(L)1 inhibitors plus chemotherapy | 5 | 71.27 0.01 | 0.17 | 0.06–0.31 | 31.59 |
| Overall pooled Grade≥ 3 irAEs rate | 16 | 69.83 0.00 | 0.15 | 0.09–0.22 | 100 |